| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 16 | 2024 | 254 | 4.530 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 5 | 2022 | 23 | 3.360 |
Why?
|
| Atrial Fibrillation | 17 | 2022 | 357 | 3.030 |
Why?
|
| Electrocardiography | 19 | 2024 | 497 | 2.350 |
Why?
|
| Heart Rate | 10 | 2024 | 498 | 1.750 |
Why?
|
| Heart Atria | 7 | 2022 | 282 | 1.620 |
Why?
|
| Heart Conduction System | 5 | 2023 | 112 | 1.570 |
Why?
|
| Computer Simulation | 11 | 2011 | 1101 | 1.270 |
Why?
|
| Brugada Syndrome | 8 | 2017 | 14 | 1.150 |
Why?
|
| Tachycardia | 2 | 2023 | 37 | 1.100 |
Why?
|
| Respiration | 7 | 2014 | 267 | 1.070 |
Why?
|
| Respiratory Center | 5 | 2014 | 54 | 0.990 |
Why?
|
| Cardiac Pacing, Artificial | 6 | 2024 | 103 | 0.980 |
Why?
|
| Pulmonary Veins | 5 | 2019 | 93 | 0.920 |
Why?
|
| Heart Block | 2 | 2020 | 31 | 0.900 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2023 | 2 | 0.900 |
Why?
|
| Models, Biological | 12 | 2011 | 1765 | 0.890 |
Why?
|
| Boron Neutron Capture Therapy | 8 | 2011 | 11 | 0.830 |
Why?
|
| Action Potentials | 8 | 2024 | 600 | 0.830 |
Why?
|
| Ventricular Fibrillation | 8 | 2017 | 68 | 0.810 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2011 | 412 | 0.740 |
Why?
|
| Neurons | 11 | 2014 | 1589 | 0.700 |
Why?
|
| Neurotransmitter Agents | 3 | 2010 | 108 | 0.690 |
Why?
|
| Thromboembolism | 2 | 2017 | 122 | 0.640 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2024 | 54 | 0.640 |
Why?
|
| Respiratory Mechanics | 4 | 2014 | 102 | 0.640 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2018 | 1 | 0.630 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2018 | 3 | 0.630 |
Why?
|
| Heart Ventricles | 4 | 2018 | 786 | 0.600 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 613 | 0.590 |
Why?
|
| Vibration | 1 | 2017 | 50 | 0.570 |
Why?
|
| Synaptic Transmission | 7 | 2019 | 228 | 0.570 |
Why?
|
| Humans | 73 | 2024 | 89864 | 0.540 |
Why?
|
| Knee Joint | 1 | 2017 | 165 | 0.540 |
Why?
|
| Transcription, Genetic | 5 | 2017 | 1158 | 0.530 |
Why?
|
| Locomotion | 1 | 2017 | 140 | 0.530 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 145 | 0.530 |
Why?
|
| Syncope | 4 | 2016 | 34 | 0.500 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 266 | 0.500 |
Why?
|
| Brain Neoplasms | 7 | 2011 | 783 | 0.490 |
Why?
|
| Norepinephrine | 2 | 2014 | 172 | 0.490 |
Why?
|
| Male | 58 | 2024 | 42614 | 0.460 |
Why?
|
| Anticoagulants | 1 | 2017 | 431 | 0.450 |
Why?
|
| Glutamic Acid | 2 | 2019 | 154 | 0.440 |
Why?
|
| Bundle of His | 2 | 2024 | 46 | 0.430 |
Why?
|
| Periodicity | 3 | 2013 | 119 | 0.430 |
Why?
|
| Female | 49 | 2024 | 46529 | 0.430 |
Why?
|
| Tachycardia, Ventricular | 4 | 2024 | 124 | 0.420 |
Why?
|
| Hypoxia | 4 | 2014 | 657 | 0.420 |
Why?
|
| Borohydrides | 4 | 2011 | 7 | 0.420 |
Why?
|
| Nerve Net | 2 | 2014 | 374 | 0.410 |
Why?
|
| Middle Aged | 37 | 2024 | 26103 | 0.410 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 2328 | 0.400 |
Why?
|
| Time Factors | 15 | 2024 | 5357 | 0.400 |
Why?
|
| Sulfhydryl Compounds | 4 | 2011 | 71 | 0.400 |
Why?
|
| Glioma | 4 | 2011 | 294 | 0.390 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2017 | 27 | 0.380 |
Why?
|
| Somatosensory Cortex | 3 | 2007 | 146 | 0.370 |
Why?
|
| Biological Clocks | 2 | 2011 | 74 | 0.370 |
Why?
|
| Lidocaine | 4 | 2017 | 65 | 0.360 |
Why?
|
| Patch-Clamp Techniques | 9 | 2019 | 396 | 0.350 |
Why?
|
| Drug Delivery Systems | 2 | 2011 | 178 | 0.350 |
Why?
|
| Animals | 34 | 2022 | 27516 | 0.340 |
Why?
|
| Aged | 28 | 2024 | 19230 | 0.340 |
Why?
|
| Defibrillators, Implantable | 3 | 2016 | 146 | 0.330 |
Why?
|
| Signal Transduction | 11 | 2016 | 3403 | 0.330 |
Why?
|
| Kidney Transplantation | 5 | 2018 | 855 | 0.330 |
Why?
|
| Gene Expression Profiling | 7 | 2023 | 1452 | 0.330 |
Why?
|
| ROC Curve | 5 | 2018 | 778 | 0.320 |
Why?
|
| Software | 5 | 2011 | 669 | 0.320 |
Why?
|
| Cryosurgery | 2 | 2019 | 54 | 0.320 |
Why?
|
| Japan | 10 | 2024 | 304 | 0.310 |
Why?
|
| Recurrence | 6 | 2019 | 1144 | 0.310 |
Why?
|
| Ventricular Function, Right | 1 | 2009 | 150 | 0.310 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2017 | 65 | 0.310 |
Why?
|
| Risk Assessment | 10 | 2019 | 2324 | 0.310 |
Why?
|
| Risk Factors | 11 | 2019 | 5548 | 0.300 |
Why?
|
| Glycolysis | 3 | 2022 | 135 | 0.300 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2024 | 72 | 0.290 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2015 | 348 | 0.290 |
Why?
|
| Mice | 14 | 2022 | 11846 | 0.280 |
Why?
|
| Granzymes | 2 | 2023 | 95 | 0.270 |
Why?
|
| Lac Operon | 2 | 2004 | 47 | 0.270 |
Why?
|
| Brain Stem | 4 | 2014 | 167 | 0.270 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2006 | 9 | 0.260 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2006 | 43 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 1729 | 0.250 |
Why?
|
| Atrioventricular Node | 1 | 2005 | 35 | 0.250 |
Why?
|
| Exercise Test | 3 | 2019 | 166 | 0.250 |
Why?
|
| Adult | 21 | 2020 | 26784 | 0.240 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2004 | 23 | 0.240 |
Why?
|
| Neck Injuries | 1 | 2004 | 13 | 0.240 |
Why?
|
| User-Computer Interface | 2 | 2003 | 187 | 0.240 |
Why?
|
| Head Protective Devices | 1 | 2004 | 20 | 0.240 |
Why?
|
| Cell Membrane | 1 | 2007 | 677 | 0.230 |
Why?
|
| Membrane Potentials | 6 | 2019 | 436 | 0.230 |
Why?
|
| Cardiac Output | 1 | 2024 | 155 | 0.230 |
Why?
|
| Accidents, Traffic | 1 | 2004 | 98 | 0.220 |
Why?
|
| Immune System Diseases | 1 | 2023 | 27 | 0.220 |
Why?
|
| In Vitro Techniques | 7 | 2019 | 996 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2016 | 222 | 0.210 |
Why?
|
| Syncope, Vasovagal | 1 | 2002 | 3 | 0.210 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2023 | 135 | 0.210 |
Why?
|
| Rats | 13 | 2019 | 4048 | 0.210 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2002 | 2 | 0.200 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2002 | 22 | 0.200 |
Why?
|
| Posture | 1 | 2002 | 125 | 0.200 |
Why?
|
| Sodium Channel Blockers | 3 | 2014 | 27 | 0.200 |
Why?
|
| Echocardiography | 4 | 2018 | 944 | 0.200 |
Why?
|
| Atrial Function, Left | 3 | 2019 | 51 | 0.200 |
Why?
|
| Presynaptic Terminals | 1 | 2002 | 41 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 1 | 2022 | 55 | 0.200 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 85 | 0.190 |
Why?
|
| Hemodynamics | 1 | 2005 | 738 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2024 | 337 | 0.190 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2021 | 11 | 0.190 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2003 | 217 | 0.180 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2020 | 15 | 0.180 |
Why?
|
| Hepatocytes | 1 | 2022 | 122 | 0.180 |
Why?
|
| Capsid Proteins | 1 | 2020 | 32 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 200 | 0.180 |
Why?
|
| BK Virus | 1 | 2020 | 24 | 0.180 |
Why?
|
| Physical Conditioning, Animal | 1 | 2020 | 19 | 0.180 |
Why?
|
| Polyomavirus Infections | 1 | 2020 | 29 | 0.180 |
Why?
|
| Fibromyalgia | 1 | 2020 | 14 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 312 | 0.180 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 310 | 0.170 |
Why?
|
| Escherichia coli | 1 | 2003 | 607 | 0.170 |
Why?
|
| Incidence | 4 | 2019 | 1600 | 0.170 |
Why?
|
| Gene Expression Regulation | 6 | 2016 | 1983 | 0.170 |
Why?
|
| Chromaffin Cells | 1 | 2019 | 37 | 0.170 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 55 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 983 | 0.170 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2021 | 188 | 0.170 |
Why?
|
| Exocytosis | 1 | 2019 | 109 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 120 | 0.160 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 3 | 0.160 |
Why?
|
| Troponin T | 1 | 2019 | 39 | 0.160 |
Why?
|
| Calcium Signaling | 1 | 2019 | 138 | 0.160 |
Why?
|
| Substantia Gelatinosa | 3 | 2019 | 4 | 0.160 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2018 | 6 | 0.160 |
Why?
|
| Polycythemia | 1 | 2018 | 8 | 0.160 |
Why?
|
| Spinal Cord | 3 | 2005 | 255 | 0.160 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2018 | 14 | 0.160 |
Why?
|
| Boron Compounds | 3 | 2009 | 20 | 0.160 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2018 | 16 | 0.160 |
Why?
|
| Spinal Cord Diseases | 1 | 2018 | 29 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 21 | 0.150 |
Why?
|
| Logistic Models | 3 | 2017 | 1214 | 0.150 |
Why?
|
| Excitatory Postsynaptic Potentials | 4 | 2019 | 88 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2020 | 320 | 0.150 |
Why?
|
| Circadian Rhythm | 3 | 2018 | 303 | 0.150 |
Why?
|
| Hypokalemia | 2 | 2016 | 23 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2024 | 8264 | 0.150 |
Why?
|
| Ankle Joint | 1 | 2017 | 47 | 0.140 |
Why?
|
| Rivaroxaban | 1 | 2017 | 12 | 0.140 |
Why?
|
| Flufenamic Acid | 2 | 2014 | 13 | 0.140 |
Why?
|
| Riluzole | 2 | 2014 | 15 | 0.140 |
Why?
|
| Dabigatran | 1 | 2017 | 25 | 0.140 |
Why?
|
| Anesthetics | 2 | 2007 | 53 | 0.140 |
Why?
|
| Hindlimb | 1 | 2017 | 96 | 0.140 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 16 | 0.140 |
Why?
|
| Lighting | 1 | 2017 | 33 | 0.140 |
Why?
|
| Range of Motion, Articular | 1 | 2017 | 157 | 0.140 |
Why?
|
| Neural Pathways | 2 | 2010 | 319 | 0.140 |
Why?
|
| Heart Failure | 2 | 2017 | 1252 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2017 | 693 | 0.140 |
Why?
|
| Walking | 1 | 2017 | 93 | 0.140 |
Why?
|
| Pyridones | 1 | 2017 | 56 | 0.140 |
Why?
|
| Photons | 1 | 2017 | 47 | 0.140 |
Why?
|
| Organ Culture Techniques | 2 | 2014 | 135 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 5 | 0.140 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2016 | 27 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 304 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2019 | 165 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2009 | 264 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 599 | 0.130 |
Why?
|
| Heparin | 1 | 2017 | 185 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2017 | 150 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2021 | 556 | 0.130 |
Why?
|
| Neural Inhibition | 2 | 2010 | 97 | 0.130 |
Why?
|
| Benzazepines | 1 | 2016 | 64 | 0.130 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 477 | 0.130 |
Why?
|
| Electrophysiology | 2 | 2009 | 403 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 3468 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2016 | 159 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 185 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2018 | 479 | 0.130 |
Why?
|
| Liver | 2 | 2022 | 1211 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 380 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 434 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 358 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6779 | 0.120 |
Why?
|
| Brain Infarction | 1 | 2015 | 23 | 0.120 |
Why?
|
| Seasons | 1 | 2016 | 239 | 0.120 |
Why?
|
| Prognosis | 8 | 2017 | 3789 | 0.120 |
Why?
|
| Sensitivity and Specificity | 7 | 2016 | 2018 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 305 | 0.120 |
Why?
|
| Dinoprostone | 1 | 2014 | 70 | 0.120 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 60 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2019 | 1237 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2024 | 4322 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 2766 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2018 | 905 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 399 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1607 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 168 | 0.110 |
Why?
|
| Metabolism | 2 | 2004 | 24 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2014 | 102 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 73 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 2676 | 0.110 |
Why?
|
| Survival Rate | 3 | 2013 | 1898 | 0.110 |
Why?
|
| Calcium Channels, N-Type | 1 | 2013 | 17 | 0.110 |
Why?
|
| Intracranial Embolism | 1 | 2013 | 29 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2015 | 508 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 57 | 0.110 |
Why?
|
| Arousal | 1 | 2013 | 170 | 0.110 |
Why?
|
| Multienzyme Complexes | 2 | 2003 | 64 | 0.110 |
Why?
|
| Atrial Flutter | 1 | 2012 | 36 | 0.100 |
Why?
|
| Young Adult | 4 | 2019 | 6389 | 0.100 |
Why?
|
| Sick Sinus Syndrome | 1 | 2012 | 9 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 3670 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 716 | 0.100 |
Why?
|
| Animals, Newborn | 2 | 2013 | 524 | 0.100 |
Why?
|
| PPAR alpha | 2 | 2009 | 10 | 0.100 |
Why?
|
| Rats, Wistar | 5 | 2007 | 303 | 0.100 |
Why?
|
| Fenofibrate | 2 | 2009 | 20 | 0.100 |
Why?
|
| Genomics | 3 | 2011 | 776 | 0.100 |
Why?
|
| Transferrin | 2 | 2011 | 19 | 0.100 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2012 | 23 | 0.100 |
Why?
|
| Amiodarone | 1 | 2011 | 14 | 0.100 |
Why?
|
| Liposomes | 2 | 2011 | 93 | 0.100 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 103 | 0.100 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2011 | 9 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 889 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2013 | 357 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2014 | 258 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 899 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2019 | 9185 | 0.090 |
Why?
|
| Kidney | 1 | 2016 | 1148 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 222 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2013 | 328 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 848 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2010 | 7 | 0.090 |
Why?
|
| Ketanserin | 1 | 2010 | 10 | 0.090 |
Why?
|
| Isoindoles | 1 | 2010 | 14 | 0.090 |
Why?
|
| Locus Coeruleus | 1 | 2010 | 5 | 0.090 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2010 | 8 | 0.090 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2010 | 15 | 0.090 |
Why?
|
| Hypoglossal Nerve | 1 | 2010 | 27 | 0.090 |
Why?
|
| Microinjections | 1 | 2010 | 71 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 35 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 159 | 0.090 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2010 | 35 | 0.090 |
Why?
|
| Raphe Nuclei | 1 | 2010 | 37 | 0.090 |
Why?
|
| Phenylalanine | 2 | 2009 | 36 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2012 | 395 | 0.090 |
Why?
|
| Coronary Sinus | 1 | 2009 | 8 | 0.090 |
Why?
|
| Mitral Valve | 1 | 2012 | 264 | 0.090 |
Why?
|
| Electromyography | 1 | 2010 | 195 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1244 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 52 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2009 | 97 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2022 | 2887 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 365 | 0.080 |
Why?
|
| Autocrine Communication | 1 | 2009 | 20 | 0.080 |
Why?
|
| Piperidines | 1 | 2010 | 163 | 0.080 |
Why?
|
| Synapses | 2 | 2013 | 280 | 0.080 |
Why?
|
| Software Design | 2 | 2005 | 17 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 94 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1532 | 0.080 |
Why?
|
| Sodium | 2 | 2016 | 332 | 0.080 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Observer Variation | 1 | 2009 | 614 | 0.080 |
Why?
|
| Drosophila melanogaster | 2 | 2011 | 614 | 0.070 |
Why?
|
| Pentobarbital | 1 | 2007 | 20 | 0.070 |
Why?
|
| GABA Agonists | 1 | 2007 | 20 | 0.070 |
Why?
|
| Creatinine | 2 | 2020 | 294 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2007 | 33 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2016 | 1665 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 293 | 0.070 |
Why?
|
| Bayes Theorem | 3 | 2021 | 381 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2019 | 2015 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 80 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2007 | 66 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 87 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2392 | 0.070 |
Why?
|
| Boron | 1 | 2007 | 2 | 0.070 |
Why?
|
| Isoflurane | 1 | 2007 | 64 | 0.070 |
Why?
|
| Calcium Channels, Q-Type | 2 | 2019 | 8 | 0.070 |
Why?
|
| Calcium Channels, P-Type | 2 | 2019 | 10 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 854 | 0.070 |
Why?
|
| Cranial Irradiation | 1 | 2006 | 40 | 0.070 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2006 | 28 | 0.070 |
Why?
|
| Antimetabolites | 1 | 2006 | 24 | 0.070 |
Why?
|
| Analgesics | 1 | 2007 | 119 | 0.070 |
Why?
|
| Ribonucleosides | 1 | 2006 | 25 | 0.070 |
Why?
|
| Mice, Inbred ICR | 2 | 2017 | 73 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 132 | 0.070 |
Why?
|
| Meningioma | 1 | 2006 | 62 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2006 | 66 | 0.070 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 6 | 0.070 |
Why?
|
| Gliosarcoma | 1 | 2006 | 7 | 0.070 |
Why?
|
| Information Science | 1 | 2005 | 2 | 0.070 |
Why?
|
| Calcium | 2 | 2019 | 1179 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 46 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 3250 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 31 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2008 | 816 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2009 | 464 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2006 | 66 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 360 | 0.060 |
Why?
|
| Documentation | 2 | 2003 | 103 | 0.060 |
Why?
|
| Pain, Intractable | 1 | 2005 | 10 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 276 | 0.060 |
Why?
|
| Iodobenzenes | 1 | 2004 | 1 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 977 | 0.060 |
Why?
|
| Thallium | 1 | 2004 | 8 | 0.060 |
Why?
|
| Computational Biology | 2 | 2006 | 551 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2012 | 2301 | 0.060 |
Why?
|
| Angina Pectoris | 1 | 2004 | 29 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2006 | 212 | 0.060 |
Why?
|
| Stroke | 1 | 2013 | 994 | 0.060 |
Why?
|
| Amphiregulin | 1 | 2023 | 6 | 0.060 |
Why?
|
| Pyruvic Acid | 1 | 2004 | 12 | 0.060 |
Why?
|
| Guanosine Diphosphate | 1 | 2003 | 19 | 0.060 |
Why?
|
| Exons | 1 | 2006 | 453 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 32 | 0.060 |
Why?
|
| Occipital Bone | 1 | 2004 | 18 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2003 | 33 | 0.060 |
Why?
|
| Adenosine Diphosphate | 1 | 2004 | 56 | 0.060 |
Why?
|
| Sarcoma | 1 | 2006 | 219 | 0.060 |
Why?
|
| Skull Neoplasms | 1 | 2004 | 30 | 0.060 |
Why?
|
| NAD | 1 | 2004 | 72 | 0.060 |
Why?
|
| Lactose | 1 | 2004 | 27 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2004 | 141 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2004 | 134 | 0.060 |
Why?
|
| Dura Mater | 1 | 2004 | 44 | 0.060 |
Why?
|
| Biology | 1 | 2004 | 52 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 2004 | 43 | 0.060 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 13 | 0.050 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 16 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2006 | 1350 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2006 | 948 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2006 | 1130 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 302 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 117 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2024 | 265 | 0.050 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 24 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2007 | 756 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 316 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 412 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 319 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2002 | 36 | 0.050 |
Why?
|
| Aconitine | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ganglia, Sensory | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ventromedial Hypothalamic Nucleus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ouabain | 1 | 2002 | 24 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 48 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2011 | 1542 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2002 | 55 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2022 | 145 | 0.050 |
Why?
|
| Graft Rejection | 3 | 2018 | 1076 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 153 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 326 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2022 | 155 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 557 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 127 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 395 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 82 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1774 | 0.050 |
Why?
|
| Receptors, Nicotinic | 1 | 2002 | 131 | 0.050 |
Why?
|
| Benzamides | 1 | 2002 | 234 | 0.050 |
Why?
|
| Reserpine | 1 | 2020 | 5 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2022 | 245 | 0.050 |
Why?
|
| Glucose | 1 | 2004 | 629 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 236 | 0.050 |
Why?
|
| Trachea | 1 | 2002 | 292 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 253 | 0.040 |
Why?
|
| Carcinoma | 1 | 2004 | 438 | 0.040 |
Why?
|
| Adolescent | 4 | 2009 | 9327 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1735 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 1704 | 0.040 |
Why?
|
| Gait | 1 | 2020 | 81 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 469 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 2019 | 33 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2583 | 0.040 |
Why?
|
| Nociception | 1 | 2019 | 5 | 0.040 |
Why?
|
| Exercise | 1 | 2002 | 327 | 0.040 |
Why?
|
| DNA Damage | 1 | 2021 | 373 | 0.040 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 13 | 0.040 |
Why?
|
| Neuralgia | 1 | 2019 | 30 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 644 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 52 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2018 | 21 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 145 | 0.040 |
Why?
|
| Syndrome | 2 | 2013 | 450 | 0.040 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 99 | 0.040 |
Why?
|
| Motor Activity | 1 | 2020 | 327 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2018 | 122 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2018 | 511 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 422 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 184 | 0.040 |
Why?
|
| Mesonephros | 1 | 2017 | 1 | 0.040 |
Why?
|
| RNA Caps | 1 | 2017 | 8 | 0.040 |
Why?
|
| Gonads | 1 | 2017 | 19 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 305 | 0.040 |
Why?
|
| CLOCK Proteins | 1 | 2016 | 15 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2016 | 43 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 194 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 50 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 47 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1864 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 199 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 223 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1168 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 1799 | 0.030 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2016 | 10 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 115 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2016 | 55 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2016 | 42 | 0.030 |
Why?
|
| Vitamin A | 1 | 2016 | 28 | 0.030 |
Why?
|
| Physical Stimulation | 2 | 2007 | 72 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2019 | 411 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2016 | 79 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 515 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 89 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 245 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 289 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 468 | 0.030 |
Why?
|
| Cadmium | 1 | 2014 | 28 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 453 | 0.030 |
Why?
|
| Potassium | 1 | 2016 | 258 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 270 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 121 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 274 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 462 | 0.030 |
Why?
|
| Apoptosis | 2 | 2016 | 1717 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2006 | 296 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1121 | 0.030 |
Why?
|
| Excitation Contraction Coupling | 1 | 2013 | 8 | 0.030 |
Why?
|
| Algorithms | 3 | 2009 | 1908 | 0.030 |
Why?
|
| KATP Channels | 1 | 2013 | 19 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 981 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 56 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2013 | 64 | 0.030 |
Why?
|
| Atrial Function | 1 | 2012 | 19 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1491 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 2013 | 191 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 663 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 1309 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 252 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2495 | 0.020 |
Why?
|
| Granulocytes | 1 | 2011 | 38 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 126 | 0.020 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 238 | 0.020 |
Why?
|
| Iopamidol | 1 | 2011 | 10 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2011 | 14 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2649 | 0.020 |
Why?
|
| Animals, Outbred Strains | 1 | 2011 | 17 | 0.020 |
Why?
|
| Iodine | 1 | 2011 | 43 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 154 | 0.020 |
Why?
|
| Quality of Life | 1 | 2019 | 1680 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 1576 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 682 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2009 | 2025 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 952 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 886 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 661 | 0.020 |
Why?
|
| Intercostal Muscles | 1 | 2009 | 5 | 0.020 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1048 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1227 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 958 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1929 | 0.020 |
Why?
|
| Biometry | 1 | 2009 | 66 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 416 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1250 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 691 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 158 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 116 | 0.020 |
Why?
|
| Homeostasis | 1 | 2011 | 418 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 81 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 247 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 726 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 294 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 682 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2009 | 269 | 0.020 |
Why?
|
| Ions | 1 | 2007 | 75 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 120 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2006 | 84 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 194 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 397 | 0.020 |
Why?
|
| Pancreas Transplantation | 1 | 2006 | 104 | 0.020 |
Why?
|
| Brain | 2 | 2007 | 2303 | 0.020 |
Why?
|
| DNA Probes | 1 | 2006 | 77 | 0.020 |
Why?
|
| Azathioprine | 1 | 2006 | 124 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 203 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 290 | 0.020 |
Why?
|
| Asthma | 1 | 2013 | 983 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2006 | 73 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 307 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2006 | 130 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2006 | 369 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 179 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 437 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2009 | 864 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2006 | 476 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 337 | 0.010 |
Why?
|
| Nociceptors | 1 | 2004 | 30 | 0.010 |
Why?
|
| Cesium | 1 | 2003 | 25 | 0.010 |
Why?
|
| Reoperation | 1 | 2006 | 604 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2003 | 32 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 222 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 134 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 51 | 0.010 |
Why?
|
| Huntington Disease | 1 | 2004 | 39 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2003 | 55 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 2004 | 77 | 0.010 |
Why?
|
| Genes, myc | 1 | 2003 | 40 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2003 | 43 | 0.010 |
Why?
|
| Radiosurgery | 1 | 2006 | 287 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 196 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 49 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 565 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 177 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 107 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 576 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 1184 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 389 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 162 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 571 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 169 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 744 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 431 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1255 | 0.010 |
Why?
|
| Gastrointestinal Agents | 1 | 2002 | 174 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 3040 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1180 | 0.010 |
Why?
|